Adaptimmune Therapeutics PLC - Company Profile (NASDAQ:ADAP)

Analyst Ratings

Consensus Ratings for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (129.59% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetActions
4/24/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Deutsche Bank AGInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015SunTrust Banks Inc.Initiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015GuggenheimInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Bank of America Corp.Initiated CoverageNeutral$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.19)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.20)($0.16)($0.18)
Q2 20163($0.26)($0.19)($0.22)
Q3 20162($0.31)($0.20)($0.26)
Q4 20162($0.40)($0.26)($0.33)
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateHeadline
07/26/16 02:18 PMAdaptimmune Therapeutics (ADAP) Receives EC Orphan Drug Designation for NY-ESO SPEAR T-cell Therapy in STS - StreetInsider.com
07/26/16 07:18 AMAdaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European ...
07/26/16 07:03 AM8:03 am Adaptimmune Therapeutics announces that the EC has designated its NY-ESO SPEAR T-cell therapy as an orphan medicinal product for the treatment of soft tissue sarcoma -
07/23/16 02:18 PMStock Focus: Following Analyst Expectations on Shares of Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Engelwood Daily
07/22/16 02:18 PMCould Adaptimmune Therapeutics PLC - ADR Lose Strenght? The Stock Increases A Lot Today - Consumer Eagle
07/21/16 02:19 PMHow Analysts Feel About Adaptimmune Therapeutics PLC - ADR After Today's Huge Decline? - Consumer Eagle
07/21/16 02:19 PMEarnings Focus and Crowd Sourced Sentiment Review for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - TGP
07/21/16 02:19 PMA Reversal for Adaptimmune Therapeutics PLC - ADR Is Not Near. The Stock Rises Again - Consumer Eagle
07/20/16 10:26 AMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 10:26 AMAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Updated Price Targets - FTSE News
07/19/16 08:29 AMAdaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Shorts Decreased by 18.33% After Short Covering - Consumer Eagle
07/18/16 07:05 AMTrading Performance and Target Watch for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph
07/16/16 02:19 PMAdaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Short Interest Decreased By 3.51% - Consumer Eagle
07/14/16 02:20 PMCrowd Rating and Earnings Recap for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Telanagana Press
07/14/16 02:20 PMAdaptimmune Therapeutics plc Realized Volatility Hits Extreme Level - CML News
07/13/16 02:19 PMStrong Sell Calls For Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) At 0 - Investor Newswire
07/13/16 10:24 AMAnalyst Target and Average Rating Watch: Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph
07/12/16 07:48 PMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/10/16 07:04 AMAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Broker Price Targets For The Coming Week - Fiscal Standard
07/08/16 03:50 PMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
07/07/16 07:35 PMAdaptimmune Therapeutics plc Stock Momentum Hits Weakness - CML News
07/06/16 02:19 PMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Expected to Reach Highs Of $23 - Investor Newswire
07/04/16 02:19 PMAdaptimmune Therapeutics PLC (NASDAQ:ADAP) commercial development and supply agreement with Thermo ... - Inside Trade
07/04/16 07:05 AMAdaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Shorted Shares Decreased By 3.51% - Engelwood Daily
07/02/16 10:01 AMHarris to deliver maritime electronic warfare payloads to US Navy
07/02/16 10:01 AMQuestionable State Bid Process Leaves California HIV/AIDS Community In Jeopardy
07/01/16 02:19 PMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)'s Company Shares Decreased 26.31% After Low Volatility - Engelwood Daily
07/01/16 02:19 PMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)'s Company Shares Decreased 26.31% After Low Volatility - Engelwood Daily
06/29/16 10:30 AMBrokers Issue Average Price Target Of 19.40 On Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Fiscal Standard
06/28/16 02:32 PMAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 02:32 PMShare Update and Earnings Review for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph
06/27/16 02:40 PMEquity Research and Technical Review on Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph
06/27/16 07:04 AMNext Weeks Broker Price Targets For Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Fiscal Standard
06/24/16 02:17 PMNew Broker Ratings For Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - FTSE News
06/22/16 07:28 PMStrong Buy Calls Count For Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) At 3 - Investor Newswire
06/22/16 07:28 PMAdaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Momentum Hits Weakness - CML News
06/22/16 07:06 AMHot Line At Active Movers- Adaptimmune Therapeutics (NASDAQ:ADAP), United Continental (NYSE:UAL), QEP ... - Seneca Globe
06/21/16 02:17 PMStocks to Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Adaptimmune Therapeutics plc (NASDAQ:ADAP ... - KC Register
06/21/16 02:17 PMAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives EMA Orphan Drug Endorsement For SPEAR T-Cell Therapy - Market Exclusive
06/21/16 07:05 AMAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Current Analyst Ratings - Fiscal Standard
06/21/16 06:50 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial -
06/21/16 06:32 AMAdaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 21, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into ...
06/20/16 08:50 AMAnalyst Views For The Week Ahead: Adaptimmune Therapeutics Plc (NASDAQ:ADAP) - Fiscal Standard
06/20/16 08:50 AMAdaptimmune Therapeutics (ADAP) Announces Positive Opinion for Orphan Drug Designation in EU for SPEAR T-cell ... - StreetInsider.com
06/20/16 08:43 AMAdaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR(TM) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines ...
06/20/16 08:30 AMAdaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma - [GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency’ s Committee for Orphan ...
06/17/16 10:14 AMForm 8-K Adaptimmune Therapeutics For: Jun 16
06/16/16 11:49 AMAdaptimmune to Present at the 2016 JMP Life Sciences Conference - [at noodls] - PHILADELPHIA and OXFORD, United Kingdom, June 16, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, ...
06/16/16 05:51 AMADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Sub -
06/15/16 02:20 PMTrend Of Rating Given To Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Investor Newswire

Social

About Adaptimmune Therapeutics PLC -

Adaptimmune Therapeutics PLC - logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADAP
  • CUSIP:
Key Metrics:
  • Previous Close: $7.84
  • 50 Day Moving Average: $8.63
  • 200 Day Moving Average: $8.64
  • P/E Ratio: N/A
  • P/E Growth: 0.48
  • Market Cap: $558.49M
  • Beta: 1.18
  • Current Year EPS Consensus Estimate: $-1.12 EPS
  • Next Year EPS Consensus Estimate: $-1.06 EPS
Additional Links:
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Chart for Wednesday, July, 27, 2016